Prescription Drug Policy

Understand the implications of prescription drug policy on affordability and access for aging adults.

Public Statement

West Health Submits Comments to Federal Trade Commission on RFI Docket No. ATR 102

May 1, 2024

Issue Brief

Executive Summary | Pharmacy Benefit Manager Reforms: Can Congress Fix the Market Without Breaking It?

April 17, 2024

White Paper

Pharmacy Benefit Manager Reforms: Can Congress Fix the Market Without Breaking It?

April 17, 2024

Article

Medicare Part B Spending on Macular Degeneration Treatments Associated With Manufacturer Payments to Ophthalmologists

September 8, 2023

Article

How states can act to limit drug price increases, saving employers and workers billions

October 20, 2022

Public Statement

West Health Comments on the Business Practices of PBMs

April 25, 2022

Public Statement

Letter to CMS on 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs

March 7, 2022

Publication

Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition

November 15, 2021

Thought Leadership

Article

Americans are dying over drug costs. It’s time to let Medicare negotiate prices.

September 30, 2021

Public Polling

The Case for Lower Drug Prices for All Americans

September 24, 2021

Article

To lower drug costs, define ‘cost’ to mean net cost after rebates

September 7, 2021

Article

Two Ways to Reduce Prescription Drug Costs

July 26, 2021

Article

Limiting Coverage Based On Efficacy And Safety: A Path Forward For Medicare Regarding The Alzheimer’s Treatment Aducanumab

June 7, 2021

Video

High Drug Costs: TRx Of The Trade

May 3, 2021

Infographics & Interactives

The Burden of High Drug Prices

March 23, 2021

Publication

Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases

September 11, 2020